• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝移植后癌症的发病率及危险因素

Incidence and risk factors for cancer after liver transplantation.

作者信息

Vallejo Gonzalo Hernández, Romero Carlos Jiménez, de Vicente Juan Carlos

机构信息

Department of Oral Medicine and Surgery, School of Dentistry, Complutense University, Madrid, Spain.

出版信息

Crit Rev Oncol Hematol. 2005 Oct;56(1):87-99. doi: 10.1016/j.critrevonc.2004.12.011.

DOI:10.1016/j.critrevonc.2004.12.011
PMID:15979889
Abstract

De novo tumors (DNT) are a serious complication after orthotopic liver transplantation (OLT), showing a higher overall incidence ranging from 4.7% to 15.7% in non-selected series. Skin cancer (SC) is the most frequent malignancy observed, ranging from 6% to 70% of the tumors observed, followed by post-transplant lymphoproliferative disorders (PTLD) (4.3-30%). Different immunosuppressive protocols do not seem to influence DNT appearance. Colon and upper aerodigestive cancer after OLT seems to be more prone to develop when there are associated risk factors, such as primary sclerosing cholangitis (PSC) and alcoholic liver cirrhosis (ALC). Some risk factors, such as age, smoking, alcohol and others seem to play a role in higher risk for malignancy, but the presence of a long-term immunosuppressive state, more than the specific regimen used, is the basis for this higher incidence. Ethnic and demographic factors are also important variables influencing the heterogeneity of the results, especially influencing Kaposi's sarcoma and skin tumors.

摘要

新发肿瘤(DNT)是原位肝移植(OLT)后的一种严重并发症,在未筛选的系列研究中,其总体发病率较高,范围在4.7%至15.7%之间。皮肤癌(SC)是观察到的最常见恶性肿瘤,在所观察到的肿瘤中占6%至70%,其次是移植后淋巴细胞增生性疾病(PTLD)(4.3 - 30%)。不同的免疫抑制方案似乎并不影响DNT的出现。OLT后结肠癌和上消化道癌在存在相关危险因素时,如原发性硬化性胆管炎(PSC)和酒精性肝硬化(ALC),似乎更容易发生。一些危险因素,如年龄、吸烟、饮酒等,似乎在恶性肿瘤风险较高中起作用,但长期免疫抑制状态的存在,而非所使用的具体方案,是这种较高发病率的基础。种族和人口统计学因素也是影响结果异质性的重要变量,尤其影响卡波西肉瘤和皮肤肿瘤。

相似文献

1
Incidence and risk factors for cancer after liver transplantation.肝移植后癌症的发病率及危险因素
Crit Rev Oncol Hematol. 2005 Oct;56(1):87-99. doi: 10.1016/j.critrevonc.2004.12.011.
2
Colorectal cancer after orthotopic liver transplantation.原位肝移植术后的结直肠癌
Crit Rev Oncol Hematol. 2005 Oct;56(1):147-53. doi: 10.1016/j.critrevonc.2004.12.013.
3
De novo malignancies after liver transplantation: a major cause of late death.肝移植后新发恶性肿瘤:晚期死亡的主要原因。
Liver Transpl. 2001 Nov;7(11 Suppl 1):S109-18. doi: 10.1053/jlts.2001.28645.
4
Development of lymphoproliferative disease after liver transplantation.肝移植后淋巴增殖性疾病的发展
Transplant Proc. 2008 Nov;40(9):2988-9. doi: 10.1016/j.transproceed.2008.09.008.
5
Cancer incidence after immunosuppressive treatment following kidney transplantation.肾移植后免疫抑制治疗后的癌症发病率。
Crit Rev Oncol Hematol. 2005 Oct;56(1):71-85. doi: 10.1016/j.critrevonc.2004.11.010.
6
Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation.肝移植患者中基于移植前病因的移植后恶性肿瘤差异风险证据。
Liver Transpl. 2002 May;8(5):482-7. doi: 10.1053/jlts.2002.32977.
7
Incidence of upper aerodigestive tract cancer after liver transplantation for alcoholic cirrhosis: a 10-year experience in an Italian center.酒精性肝硬化肝移植术后上消化道癌的发病率:意大利一家中心的10年经验
Transplant Proc. 2013 Sep;45(7):2733-5. doi: 10.1016/j.transproceed.2013.08.011.
8
De novo cancers and post-transplant lymphoproliferative disorder in adult liver transplantation.成人肝移植中的新发癌症及移植后淋巴细胞增生性疾病
Pathol Int. 2006 Nov;56(11):712-5. doi: 10.1111/j.1440-1827.2006.02035.x.
9
Incidence and risk factors for the development of lung tumors after liver transplantation.
Transpl Int. 2007 Jan;20(1):57-63. doi: 10.1111/j.1432-2277.2006.00397.x.
10
Risk factors for development of de novo neoplasia after liver transplantation.
Liver Transpl. 2001 Nov;7(11):971-5. doi: 10.1053/jlts.2001.28744.

引用本文的文献

1
Incidence, screening, and management of malignancies in liver transplant patients: A review.肝移植患者恶性肿瘤的发病率、筛查与管理:综述
World J Transplant. 2025 Sep 18;15(3):101046. doi: 10.5500/wjt.v15.i3.101046.
2
Frontiers and Controversies in De Novo Gastrointestinal Tumors After Organ Transplantation: Current Progress and Future Directions.器官移植后新发胃肠道肿瘤的前沿与争议:当前进展与未来方向
Ann Surg Oncol. 2025 May;32(5):3392-3405. doi: 10.1245/s10434-025-16975-w. Epub 2025 Mar 4.
3
Cryopreserved cGMP-compliant human pluripotent stem cell-derived hepatic progenitors rescue mice from acute liver failure through rapid paracrine effects on liver cells.
经冷冻保存符合 cGMP 标准的人多能干细胞衍生的肝祖细胞通过对肝细胞的快速旁分泌作用挽救急性肝衰竭小鼠。
Stem Cell Res Ther. 2024 Mar 12;15(1):71. doi: 10.1186/s13287-024-03673-9.
4
Early occurrence of acute myelomonocytic leukemia (M4/M5) after liver transplantation: a case report.肝移植后急性髓单核细胞白血病(M4/M5)的早期发生:病例报告。
J Med Case Rep. 2023 Sep 5;17(1):398. doi: 10.1186/s13256-023-04126-2.
5
Successful pancreatoduodenectomy of duodenal malignancy after orthotopic liver transplantation: A case report.原位肝移植术后十二指肠恶性肿瘤成功实施胰十二指肠切除术:一例报告。
Front Surg. 2023 Jan 6;9:1068215. doi: 10.3389/fsurg.2022.1068215. eCollection 2022.
6
Current status of liver transplantation for non-B non-C liver cirrhosis and hepatocellular carcinoma.非B非C型肝硬化及肝细胞癌的肝移植现状
Ann Gastroenterol Surg. 2022 Aug 23;7(1):42-52. doi: 10.1002/ags3.12612. eCollection 2023 Jan.
7
Tobacco, Cigarettes, and the Liver: The Smoking Gun.烟草、香烟与肝脏:确凿证据
J Clin Exp Hepatol. 2021 Nov-Dec;11(6):700-712. doi: 10.1016/j.jceh.2021.07.016. Epub 2021 Aug 10.
8
Smoking and Liver Disease.吸烟与肝脏疾病
Gastroenterol Hepatol (N Y). 2020 Dec;16(12):617-625.
9
Pretransplant Hepatic Malignancy Increases Risk of De Novo Malignancy after Liver Transplantation.肝移植前的肝恶性肿瘤增加肝移植后新发恶性肿瘤的风险。
J Korean Med Sci. 2020 Mar 23;35(11):e69. doi: 10.3346/jkms.2020.35.e69.
10
Sirolimus and Metformin Synergistically Inhibits Colon Cancer In Vitro and In Vivo.西罗莫司和二甲双胍在体外和体内协同抑制结肠癌
J Korean Med Sci. 2017 Sep;32(9):1385-1395. doi: 10.3346/jkms.2017.32.9.1385.